An Approach to the Investigation of Thrombocytosis: Differentiating between Essential Thrombocythemia and Secondary Thrombocytosis
Table 2
Baseline characteristics and clinical risk factors for thrombocytosis categorized based on mutational landscape of ET patients with a single driver mutation.
JAK2 (N = 78)
CALR (N = 46)
MPL (N = 13)
Demographic characteristics
Age (years; mean ± SD)
72 ± 15
62 ± 15
72 ± 11
Gender (female n (%), male n (%))
51 (65), 27 (35)
24 (51), 22 (47)
10 (77), 3 (23)
BMI (kg/m2; mean ± SD)
26.0 ± 4.8
29.3 ± 6.1
28.1 ± 6.5
CBC characteristics
WBC (×109 cells/L; mean ± SD)
10.0 ± 4.2
8.0 ± 3.3
6.9 ± 3.1
Hemoglobin (g/L; mean ± SD)
135 ± 16.4
132 ± 14.3
125 ± 17.4
MCV (fL; mean ± SD)
93 ± 10.0
95 ± 9.7
103 ± 12.6
RDW (%; mean ± SD)
15.3 ± 2.6
14.9 ± 1.9
14.4 ± 2.1
MPV (fL; mean ± SD)
9.8 ± 1.0
9.2 ± 1.0
9.5 ± 1.2
Platelet count (×109 cells/L; mean ± SD)
777 ± 290
863 ± 264
619 ± 205
ANC (×109 cells/µL; mean ± SD)
6.9 ± 3.6
5.2 ± 2.5
4.8 ± 2.0
Ferritin (μg/L; mean ± SD)
115 ± 87
200 ± 186
215 ± 189
Clinical characteristics
Smoking, n (N, %)
30 (64, 47)
13 (37, 35)
4 (6, 67)
Arterial, venous thrombosis, n (%)
22 (28), 6 (8)
9 (19), 0 (0)
1 (8), 0 (0)
Prior splenectomy, n (%)
1 (1)
1 (2)
0 (0)
Active malignancy, n (%)
3 (4)
0 (0)
0 (0)
Chronic inflammatory disease, n (%)
3 (4)
2 (4)
1 (8)
Iron deficiency anemia, n (%)
5 (6)
4 (8)
1 (8)
CALR mutation category includes type 1 and type 2. BMI, body mass index; WBC, white blood cells; MCV, mean corpuscular volume; RDW, red cell distribution width; MPV, mean platelet volume; ANC, neutrophil count; JAK2, Janus Kinase 2 gene; CALR, Calreticulin gene; MPL, thrombopoietin receptor protein gene; N, sample size; n, number of patients.
